Sleep disorders contribute to mental health challenges, traumatic injuries, and increased health care utilization in active-duty service members.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.